Dr. Wood is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35233Phone+1 205-934-6600Fax+1 205-481-1280
Education & Training
- University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
- University of Alabama Medical CenterResidency, Internal Medicine, 1999 - 2002
- Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1999
Certifications & Licensure
- AL State Medical License 2001 - 2020
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 814 citationsGemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialDaniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith
Journal of Clinical Oncology. 2011-12-01 - 115 citationsPhase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).Andres Forero-Torres, Jatin J. Shah, T. E. Wood, James Posey, Ronda Carlisle
Cancer Biotherapy & Radiopharmaceuticals. 2010-02-28 - 76 citationsCA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alon...E. G. Chiorean, D. D. Von Hoff, Michele Reni, Francis P. Arena, J. R. Infante
Annals of Oncology. 2016-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: